Background Current treatment recommendations for patients with polycythemia vera call for
maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested …

… /m 2 /d idarubicin for 2 days (days 1 and 3) and 3 g/m 2 /12 h cytarabine for 3 consecutive
days. The second and the third were courses of 3 g/m … of cytarabine at 2 g/m 2 /12 h on days 1-3…

Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular …

… (either by mouth or IV), alone or in combination with IV immunoglobulin; (2)
immunosuppressant/cytotoxic drugs; (3) rituximab, administered either at the standard dose of 375 …

Predictors of chronic lymphocytic leukaemia (CLL) transformation to Richter syndrome (RS)
are not established and were investigated in 185 consecutive CLL cases. Actuarial …

… of action of the current standard drug against M. tuberculosis, pyrazinamide, is the inhibition
… 13 Pan synthetase inhibitors that were designed against M. tuberculosis inhibited T. gondii …

Simple Summary The association of venetoclax (VEN) with hypomethylating agents (HMAs)
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …

The objective of this study was to evaluate the clinical features, prognostic factors, and efficacy
of treatments in patients with blastic plasmacytoid dendritic cell neoplasm with a leukemic …

… specimens from patients enrolled in a clinical trial from the Groupe Francophone des
Myelodysplasies (GFM), all of whom had been treated with the same DAC regimen of 20 mg/m 2 /…

The purpose of this study was to develop a flow cytometric approach to the evaluation of
marrow dysplasia in myelodysplastic syndromes (MDS). We first studied a cohort of 103 MDS …